Skip to main content
ELUT
NASDAQ Life Sciences

Elutia Q3: $1.1M Sales, $29.1M Cash, NXT-41x FDA Filing Set for Q4

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.751
Mkt Cap
$33.257M
52W Low
$0.5
52W High
$1.385
52W Position info
50% above low
Off High info
46% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

ELUT sits 50% above its 52-week low of $0.5.

Summary

Elutia reported Q3 2026 sales of $1.1 million and a $1.3 million net loss, with $29.1 million of cash, and said it will submit NXT-41x to the FDA in Q4 2026, funded through launch without an equity offering.


Key Events · Earnings and Guidance · ELUT

  • Q3 Sales Grow 20% to $1.1M

    Net sales rose to $1.1 million from $0.9 million a year earlier, with adjusted gross margin of 85.5%.

  • NXT-41x FDA Filing Set for Q4

    The GLP rabbit study met prespecified endpoints, eradicating 8-log MRSA and 6-log E. coli challenges; Elutia plans to submit NXT-41x to the FDA in Q4 2026, with NXT-41 clearance expected this quarter and NXT-41x clearance in 1H 2027.

  • $26M Raised Without Equity

    The Avenue loan, SimpliDerm sale, and Boston Scientific holdback added $26 million in 51 days; cash was $29.1 million at September 30, 2026, before the $8 million holdback received October 1.

  • Losses Continue on R&D Spend

    Continuing operations lost $6.5 million versus $1.0 million a year earlier as R&D rose $1.9 million; the $1.3 million net loss included $5.2 million of income from discontinued operations.


Analysis · ELUT · Life Sciences

The path to NXT-41x is the main event in Elutia's Q3 update: the GLP rabbit study cleared its endpoints, the FDA submission is planned for Q4 2026, and management says $26 million raised in 51 days without selling equity funds the company through clearance and the first full year of launch in 2028. Revenue remains tiny at $1.1 million, and the $1.3 million net loss was flattered by $5.2 million of income from discontinued operations while continuing operations lost $6.5 million. Regulatory timing and the Nasdaq delisting issue previously disclosed remain the key risks; a clearance decision on NXT-41 is expected this quarter.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ELUT was trading at $0.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.3M. The 52-week trading range was $0.50 to $1.39. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ELUT - Latest Insights

ELUT
Nov 05, 2026, 4:17 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.7509
Real-time Price: $0.8359 info
Change: +$0.085 (+11%) info
Market Cap: $37.021M info
ELUT
Aug 21, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9509
Real-time Price: $0.8359 info
Change: -$0.115 (-12%) info
Market Cap: $37.021M info
ELUT
Aug 14, 2026, 4:45 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.941
Real-time Price: $0.8359 info
Change: -$0.1051 (-11%) info
Market Cap: $37.021M info
ELUT
Aug 13, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.871701
Real-time Price: $0.8359 info
Change: -$0.035801 (-4%) info
Market Cap: $37.021M info
ELUT
Aug 13, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.7914
Real-time Price: $0.8359 info
Change: +$0.0445 (+6%) info
Market Cap: $37.021M info